Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study
AK Nooka, JL Kaufman, C Rodriguez… - British Journal of …, 2024 - Wiley Online Library
Due in part to racial disparities and underrepresentation in clinical studies, optimal therapies
for Black patients with multiple myeloma remain undefined. This final analysis of GRIFFIN by …
for Black patients with multiple myeloma remain undefined. This final analysis of GRIFFIN by …
[HTML][HTML] The Role of Autologous Stem Cell Transplantation in the Treatment of Newly Diagnosed Multiple Myeloma: Is It Time to Rethink the Paradigm in the Era of …
PG Richardson - Hemato, 2024 - mdpi.com
High-dose melphalan (HDM) plus autologous stem cell transplant (ASCT) remains a
standard-of-care treatment approach for eligible patients with newly diagnosed multiple …
standard-of-care treatment approach for eligible patients with newly diagnosed multiple …
Daratumumab combinations for patients with newly diagnosed and relapsed multiple myeloma
R Popat, SJ Chavda - The Lancet Haematology, 2023 - thelancet.com
Comment www. thelancet. com/haematology Vol 10 October 2023 e789 12· 4 months [95%
CI 8· 3–19· 3] vs 6· 9 months [5· 5–9· 3]; HR 0· 63 [95% CI 0· 47–0· 85]; p= 0· 0018). 10 In this …
CI 8· 3–19· 3] vs 6· 9 months [5· 5–9· 3]; HR 0· 63 [95% CI 0· 47–0· 85]; p= 0· 0018). 10 In this …
Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?
NS Callander - The Lancet Haematology, 2024 - thelancet.com
In the past 15 years, treatment frameworks for newly diagnosed multiple myeloma have
radically changed. It is important to recall that as recently as 2010, Rajkumar and …
radically changed. It is important to recall that as recently as 2010, Rajkumar and …
Health‐related quality of life in transplant‐eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and …
R Silbermann, J Laubach, JL Kaufman… - American Journal of …, 2024 - Wiley Online Library
In the phase 2 GRIFFIN trial (ClinicalTrials. gov identifier: NCT02874742), daratumumab
added to lenalidomide, bortezomib, and dexamethasone (D‐RVd) improved depth of …
added to lenalidomide, bortezomib, and dexamethasone (D‐RVd) improved depth of …
The Year of the Bispecific
SZ Usmani - The Hematologist, 2024 - ashpublications.org
The year 2023 saw many advances in both the biologic understanding of multiple myeloma
(MM) and clarity around frontline therapeutic approaches. The latter was quite evident with …
(MM) and clarity around frontline therapeutic approaches. The latter was quite evident with …
Four Is Better Than Three: Will We Finally Agree?
A Chung, A Kumar, A Chari - The Hematologist, 2024 - ashpublications.org
The phase II GRIFFIN study investigated the effects of adding the anti-CD38 monoclonal
antibody (mAb) daratumumab in intravenous form to treatment with bortezomib …
antibody (mAb) daratumumab in intravenous form to treatment with bortezomib …
The Role of Autologous Stem Cell Transplant in Ultra-High-Risk Myeloma: Do the Ends Still Justify the Means?
B Paul - … and Cellular Therapy, Official Publication of the …, 2023 - astctjournal.org
journal homepage: www. astctjournal. org consolidation after induction therapy [15]. Of the
patients included in the analysis, 12 (15%) had 3 high-risk abnormalities. The vast majority …
patients included in the analysis, 12 (15%) had 3 high-risk abnormalities. The vast majority …
[PDF][PDF] Factors affecting prognosis of MGUS and multiple myeloma
K Lemonakis - 2024 - portal.research.lu.se
Multiple myeloma (MM) is a malignant plasma cell disease preceded by an asymptomatic
state called monoclonal gammopathy of undetermined significance (MGUS). Although …
state called monoclonal gammopathy of undetermined significance (MGUS). Although …
Original Paper Optimizing individualized therapy decision-making in multiple myeloma (MM): Integration and impact of the Revised Myeloma Comorbidity Index in the …
E Dreyling, G Ihorst, H Reinhardt, J Räder, M Holler… - 2024 - researchsquare.com
Abstract Introduction: Multiple Myeloma (MM) is a hematological disease predominantly
affecting elderly patients. The complexity of current treatment necessitates individualized …
affecting elderly patients. The complexity of current treatment necessitates individualized …